The acquisition of this resident memory T cell phenotype (TRM) also includes up-regulation of checkpoint proteins including PD-1, rationalising the efficacy of PD-1 inhibitor trials and supported by in vitro tumour cell killing by CD8+ CD103+ cells when under PD-1 blockade [16]. This evidence concerns the gene CD8A and neoplasm.